The puzzle of overactive bladder: controversies, inconsistencies, and insights
- PMID: 16362142
- DOI: 10.1007/s00192-005-0032-3
The puzzle of overactive bladder: controversies, inconsistencies, and insights
Abstract
Overactive bladder (OAB) affects millions of individuals and may severely impair the quality of life of those affected. The contribution of human behavior to manifestations of this symptom complex remains poorly understood. Continued evolution of our understanding of the pathophysiology of OAB has identified contributory mechanisms, which in turn may open new therapeutic avenues. Recent improvements in drug delivery systems represent advances in the management of OAB. However, more complete symptom control with greater tolerability is desirable; this awaits the development of agents specific for newly emerging and as yet unidentified pathophysiologic pathways. Importantly, as understanding of outcomes assessment in OAB matures, refined assessments of disease severity, response to intervention, and patient preference should be possible.
Similar articles
-
Overactive bladder: recognition requires vigilance for symptoms.Cleve Clin J Med. 2007 May;74 Suppl 3:S21-9. doi: 10.3949/ccjm.74.suppl_3.s21. Cleve Clin J Med. 2007. PMID: 17546830 Review.
-
Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.Neurourol Urodyn. 2012 Nov;31(8):1258-65. doi: 10.1002/nau.22252. Epub 2012 Aug 20. Neurourol Urodyn. 2012. PMID: 22907761
-
Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial.Curr Urol Rep. 2002 Oct;3(5):343-4. doi: 10.1007/s11934-002-0074-8. Curr Urol Rep. 2002. PMID: 12354340 No abstract available.
-
The effects of reformulation: improved therapeutic index.Curr Urol Rep. 2008 Nov;9(6):465-71. doi: 10.1007/s11934-008-0080-6. Curr Urol Rep. 2008. PMID: 18947511
-
Overactive bladder disease: the urge for better therapies.J Manag Care Pharm. 2008 May;14(4):381-6. doi: 10.18553/jmcp.2008.14.4.381. J Manag Care Pharm. 2008. PMID: 18500915 Free PMC article. Review. No abstract available.
Cited by
-
Urodynamic Effects of Propiverine on Detrusor Overactivity and Abdominal Straining during Voiding in Awake Rats with Intravesical Prostaglandin E(2) Instillation.Korean J Urol. 2010 Jan;51(1):64-9. doi: 10.4111/kju.2010.51.1.64. Epub 2010 Jan 21. Korean J Urol. 2010. PMID: 20414414 Free PMC article.
-
Management of overactive bladder with transdermal oxybutynin.Rev Urol. 2006 Summer;8(3):93-103. Rev Urol. 2006. PMID: 17043706 Free PMC article.
-
Improving the clinical prediction of detrusor overactivity by utilizing additional symptoms and signs to overactive bladder symptoms alone.Int Urogynecol J. 2014 Aug;25(8):1115-20. doi: 10.1007/s00192-014-2362-5. Epub 2014 Mar 25. Int Urogynecol J. 2014. PMID: 24664215
-
Randomized trial of a comparison of rehabilitation or drug therapy for urgency urinary incontinence: 1-year follow-up.Int Urogynecol J. 2013 Jul;24(7):1181-9. doi: 10.1007/s00192-012-1992-8. Epub 2012 Nov 17. Int Urogynecol J. 2013. PMID: 23160873 Clinical Trial.
-
Affective Temperament Profiles of Overactive Bladder Patients.Noro Psikiyatr Ars. 2014 Sep;51(3):263-266. doi: 10.4274/npa.y6889. Epub 2014 Sep 1. Noro Psikiyatr Ars. 2014. PMID: 28360636 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical